GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, a global biopharma company, covers transaction notifications for the month of January 2026. The report was filed on January 16, 2026, and details specific share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a transaction notification regarding insider share purchases.
| Transaction Type | Instrument | Price (USD) | Volume (ADSs) | Date |
|---|---|---|---|---|
| Dividend Re-investment | American Depositary Shares (ADSs) | $50.2949 | 2,832.219 | 2026-01-14 |
| Dividend Re-investment | American Depositary Shares (ADSs) | $50.2949 | 285.772 | 2026-01-14 |
| Dividend Re-investment | American Depositary Shares (ADSs) | $50.2949 | 44.836 | 2026-01-14 |
| Dividend Re-investment | American Depositary Shares (ADSs) | $50.2200 | 91.071 | 2026-01-09 |
| Dividend Re-investment | American Depositary Shares (ADSs) | $50.2200 | 155.817 | 2026-01-09 |
| Dividend Re-investment | American Depositary Shares (ADSs) | $50.2949 | 344.244 | 2026-01-14 |
Material Changes
The filing reports no material changes to the company's financial position or operations. It solely documents the acquisition of ADSs by five executives via dividend re-investment plans following a dividend payment on January 8, 2026.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share transactions executed on the New York Stock Exchange (XNYS).
Investor Verification Points
- Dividend Execution: Verify the dividend payment date of January 8, 2026, and the subsequent re-investment execution dates of January 9 and 14, 2026.
- Share Price Consistency: Note the slight price variation between transactions on January 9 ($50.2200) and January 14 ($50.2949).
- Executive Participation: Confirm the involvement of key personnel including Dr. Hal Barron (Non-Executive Director), James Ford (SVP and Group General Counsel), Maria Martinez-Davis (President, US), and Shobie Ramakrishnan (Chief Digital and Technology Officer).
- Transaction Nature: Ensure these are classified as automatic dividend re-investments rather than discretionary open-market purchases.